Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10%

EarningsPositive

AI Analysis

Summary

Gilead outlined 2026 base business sales guidance of $29.8B-$30.1B and raised its HIV growth outlook to 9%-10%. The company provided forward-looking financial and product-specific growth expectations.

Financial Highlights

Guidance

$29.8B-$30.1B base business sales for 2026

Importance:5/10

Sentiment:

0.60

guidanceHIVrevenue outlook2026 forecast

Related Companies

$GILD

Read the original article

Published by Seeking Alpha Healthcare on August 5, 2026 1:20 AM

Read Original